CAS 1454585-06-8

Fórmula: C23H19F3N8O

InChI: InChI=1S/C23H19F3N8O/c24-13-2-1-3-14(10-13)34-12-28-20-21(31-23(32-22(20)34)33-6-8-35-9-7-33)27-11-17-29-16-5-4-15(25)18(26)19(16)30-17/h1-5,10,12H,6-9,11H2,(H,29,30)(H,27,31,32)

Clave InChI: CEBMEQPREMCWOL-UHFFFAOYSA-N

SMILES: C1COCCN1C2=NC(=C3C(=N2)N(C=N3)C4=CC(=CC=C4)F)NCC5=NC6=C(N5)C=CC(=C6F)F

SR-3029

CAS: 1454585-06-8

SR-3029

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: ≥98%

Peso molecular: 480.45

Ref: 54-BUP01753

N-((6,7-Difluoro-1H-Benzo[D]Imidazol-2-Yl)Methyl)-9-(3-Fluorophenyl)-2-Morpholino-9H-Purin-6-Amine

CAS: 1454585-06-8

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: 98%

Forma y color: Solid

Peso molecular: 480.4452

Ref: IN-DA00ABTA

N-((6,7-Difluoro-1H-Benzo[D]Imidazol-2-Yl)Methyl)-9-(3-Fluorophenyl)-2-Morpholino-9H-Purin-6-Amine

CAS: 1454585-06-8

N-((6,7-Difluoro-1H-Benzo[D]Imidazol-2-Yl)Methyl)-9-(3-Fluorophenyl)-2-Morpholino-9H-Purin-6-Amine

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: 99%

Peso molecular: 480.45

Ref: 54-PC108734

SR-3029

CAS: 1454585-06-8

SR-3029 is a potent and highly specific CK1δ/CK1ε inhibitor.

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: 99.64%

Forma y color: Solid

Peso molecular: 480.45

Ref: TM-T3972

SR-3029

CAS: 1454585-06-8

N-((6,7-Difluoro-1H-benzo[d]imidazol-2-yl)methyl)-9-(3-fluorophenyl)-2-morpholino-9H-purin-6-amine

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: 99%

Peso molecular: 480.45

Ref: IN-DG630311

SR 3029

CAS: 1454585-06-8

SR 3029 is a small-molecule drug that has potent antitumor activity. It inhibits cancer cell growth by inhibiting the signal pathways that regulate epidermal growth factor (EGF) production. SR 3029 is effective in animal models of metastatic colorectal cancer and skin tumor formation. In addition, SR 3029 has been shown to inhibit platinum-based chemotherapy, which may be due to its ability to target the cancer tissues and prevent metastasis.

Fórmula: C₂₃H₁₉F₃N₈O

Pureza: Min. 95%

Peso molecular: 480.45 g/mol

Ref: 3D-EIC58506